Capital Medical University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Hepatitis B
FollowWhat is new in Hepatitis B research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- AHB-137Phase 3 · NCT06829329 · NCT07897448 · NCT07069569 · NCT07246889 · NCT07876856 · NCT07370207 · NCT07137910 · NCT07654283 · NCT06993480 · NCT07635186
- Anti-HBV antiviral prophylaxisPhase 3 · NCT03343431
- AZVUDINEPhase 3 · NCT07307586
- Bimmugen® InjectionPhase 3 · NCT07793513
- BK1803Phase 3 · NCT07793513
- Diluted I.V.-Hepabig inj(GC5103)Phase 3 · NCT05686759
- EntecavirPhase 3 · NCT05453435 · NCT06966232
- Entecavir dispersible tabletsPhase 3 · NCT06150014 · NCT07797231
- GOBIK Aqueous Suspension SyringesPhase 3 · NCT07793513
- GST-HG141Phase 3 · NCT07709520 · NCT07090759 · NCT07588009
- GST-HG141 PlaceboPhase 3 · NCT07709520 · NCT07090759
- hepatitis B vaccinePhase 3 · NCT06888479 · NCT07069569
- HIV PrEP - choice of F/TDF, F/TAF, or CAB-LAPhase 3 · NCT07658976
- HRS-5635 InjectionPhase 3 · NCT06425341 · NCT07606950
- Hydronidone (270mg)Phase 3 · NCT07412236
- Hydronidone (Placebo Group)Phase 3 · NCT07412236
- Hydronidone capsulesPhase 3 · NCT05905172
- IFNα-2aPhase 3 · NCT07307586
- In-house Hepatitis B VaccinePhase 3 · NCT07854847
- In-House Recombinant Hepatitis B (Bio Farma) vaccinePhase 3 · NCT05482295
- Lamivudine Oral SolutionPhase 3 · NCT04704024
- NA therapyPhase 3 · NCT07246889 · NCT07137910
- NAs （"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF"） treatmentsPhase 3 · NCT07095855
- Obeticholic Acid 5 mgPhase 3 · NCT06691412
- PegIFNα2bPhase 3 · NCT07282249
- PlacebPhase 3 · NCT07282249
- Registered Hepatitis B VaccinePhase 3 · NCT07854847
- Registered Hepatitis B vaccine recombinant (Engerix-B)Phase 3 · NCT05482295
- STI PEP - Doxycycline as Doxy-PEPPhase 3 · NCT07658976
- TAFPhase 3 · NCT02932150 · NCT07307586 · NCT07553767
- TDF PlaceboPhase 3 · NCT01651403
- Tenofovir AlafenamidePhase 3 · NCT03489239
- Tenofovir Alafenamide Fumarate TabletsPhase 3 · NCT07797231
- Tenofovir Amibufenamide TabletsPhase 3 · NCT07797231
- Tenofovir DFPhase 3 · NCT01651403
- Tenofovir Disoproxil FumaratePhase 3 · NCT04704024
- Tenofovir Disoproxil Fumarate TabletsPhase 3 · NCT07797231
- The placebo capsulesPhase 3 · NCT05905172
- TQA3605 tabletsPhase 3 · NCT06150014 · NCT07797231
- TQA3605 tablets PlaceboPhase 3 · NCT07797231
- TVAV-008Phase 3 · NCT07282249
- Undiluted I.V.-Hepabig inj(GC5103)Phase 3 · NCT05686759
- ZM-H1505R 100mgPhase 3 · NCT07095855
- HTS 20mgPhase 2/3 · NCT07203118
- HTS 30mgPhase 2/3 · NCT07203118
- HTS 40mgPhase 2/3 · NCT07203118
- LBVDPhase 2/3 · NCT06947499
- Pentavalent vaccine and Inactivated Polio vaccinePhase 2/3 · NCT06947499
- TAF 25mgPhase 2/3 · NCT07203118
- AHB-171 InjectionPhase 2 · NCT07630727 · NCT07511218
- ALG-000184Phase 2 · NCT06963710
- Anti-PD-1 antibodyPhase 2 · NCT05769816 · NCT05771402
- anti-PD-1/anti-PD-L1 antibodyPhase 2 · NCT07845058
- BepirovirsenPhase 2 · NCT06497504 · NCT07905157 · NCT04954859 · NCT06537414 · NCT07696520 · NCT07168356
- BRII-179Phase 2 · NCT06650852
- BRII-835 (VIR-2218)Phase 2 · NCT06650852
- BW-20507 with/without NUCPhase 2 · NCT07135349
- BW-20507 with/without NUC, Peg-IFNaPhase 2 · NCT07135349
- Daplusiran/Tomligisiran Dose Level 1Phase 2 · NCT06537414
- Daplusiran/Tomligisiran Dose Level 2Phase 2 · NCT06537414
- Entecavell ODTPhase 2 · NCT07267208
- Entecavir (ETV)Phase 2 · NCT07145268
- ETV/TDF/TAFPhase 2 · NCT07852091
- GST-HG131Phase 2 · NCT07709520 · NCT06263959
- HH-006Phase 2 · NCT07519330
- HRS-5635 Injection (high dose) and Peg-IFN-αPhase 2 · NCT06425341
- HRS-5635 Injection (low dose) and Peg-IFN-αPhase 2 · NCT06425341
- HRS-5635 Injection with Peg-IFN-αPhase 2 · NCT06425341
- HT-101Phase 2 · NCT07245953 · NCT07183306
- HT-101 placeboPhase 2 · NCT07245953
- HT-102Phase 2 · NCT07245953 · NCT07183306
- HT-102 placeboPhase 2 · NCT07245953
- Imdusiran (AB-729)Phase 2 · NCT06154278
- LenvatinibPhase 2 · NCT05195294
- Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cyclePhase 2 · NCT05897138
- LioCyx-MPhase 2 · NCT05195294 · NCT06885710
- Liver biopsyPhase 2 · NCT07696520
- Methylene BluePhase 2 · NCT06887036
- NAsPhase 2 · NCT06829329 · NCT05769816 · NCT05771402 · NCT07845058
- Nucleoside (acid) analogs (NAs)Phase 2 · NCT06706310
- Optional Liver biopsyPhase 2 · NCT07696520
- Peg-IFNPhase 2 · NCT07069569
- Peg-IFN-αPhase 2 · NCT06425341
- Peg-IFNαPhase 2 · NCT05771402 · NCT07845058 · NCT06650852
- pembrolizumabPhase 2 · NCT03419481
- RosuvastatinPhase 2 · NCT05832229
- Sintilimab/EnvafolimabPhase 2 · NCT07852091
- TDFPhase 2 · NCT06963710 · NCT07553767
- Tenofovir Alafenamide CitratePhase 2 · NCT06589518
- TQA3334 TabletPhase 2 · NCT06706310
- TVAX-008Phase 2 · NCT07190742 · NCT07179653 · NCT07897448 · NCT07204236 · NCT07876856
- VIR-2218 and peginterferon alfa-2aPhase 2 · NCT06092333
- VIR-3434Phase 2 · NCT06216470
- Zinc (zinc sulphate)Phase 2 · NCT07145268
- Allogeneic Umbilical Cord Mesenchymal Stem CellPhase 1/2 · NCT04357600
- Commercial Hepatitis B vaccinePhase 1/2 · NCT03038802
- CRMA-1001Phase 1/2 · NCT07200193
- HEXASIILPhase 1/2 · NCT07855172
- Hexavalent (DTwP-HepB-rPV-Hib) VaccinePhase 1/2 · NCT07855172
- Human Umbilical Cord Mesenchymal Stem CellsPhase 1/2 · NCT05948982
- Human Umbilical Cord Mesenchymal Stem Cells InjectionPhase 1/2 · NCT07413549
- ISA104Phase 1/2 · NCT05841095
- LW231Phase 1/2 · NCT07179575
- LW231 placeboPhase 1/2 · NCT07179575
- SCG101Phase 1/2 · NCT05417932
- TenofovirPhase 1/2 · NCT06295328
- Tenofovir alafenamide fumarate tabletPhase 1/2 · NCT06150014
- Tenofovir disoproxil fumarate tabletPhase 1/2 · NCT06150014
- TerbinafinePhase 1/2 · NCT06295328
- Therapeutic hepatitis B vaccinePhase 1/2 · NCT03038802
- TherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac)Phase 1/2 · NCT06513286
- TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)Phase 1/2 · NCT06513286
- ACT201 InjectionPhase 1 · NCT07741461
- ACT201 Injection PlaceboPhase 1 · NCT07741461
- ACT500 Placebo TabletsPhase 1 · NCT07589400
- ACT500 TabletsPhase 1 · NCT07589400
- Active comparator vaccine via intramuscular injectionPhase 1 · NCT06800131
- AHB-121Phase 1 · NCT07884864
- AHB-137 injectionPhase 1 · NCT07600788
- AHB-171Phase 1 · NCT07617194
- BevacizumabPhase 1 · NCT07557251
- BRII-5395Phase 1 · NCT07557251
- EPI-003Phase 1 · NCT06661148 · NCT06745973
- GIGA-2339Phase 1 · NCT07024641
- HECN30227 injection (MAD)Phase 1 · NCT07771140
- HECN30227 injection(SAD)Phase 1 · NCT07771140
- Hepatitis B Vaccine administered trans-dermally via Microneedle Array Patch (MAP)Phase 1 · NCT06800131
- Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]Phase 1 · NCT04843852
- HepB mAb19Phase 1 · NCT05856890 · NCT06668727 · NCT07610772
- IB-001Phase 1 · NCT07389044
- LP-128 capsulesPhase 1 · NCT05130567
- mRNA HBV/TCR T-cellsPhase 1 · NCT04745403
- Nucleos(t)ide Analogue (NA)Phase 1 · NCT07617194 · NCT07511218
- PBGENE-HBVPhase 1 · NCT06680232
- Peginterferon Alfa-2APhase 1 · NCT07389044
- Peripheral ivPhase 1 · NCT03826433
- SA1211 injectionPhase 1 · NCT07275918
- SA1211 injection placeboPhase 1 · NCT07275918
- SCTA02APhase 1 · NCT07903831
- SintilimabPhase 1 · NCT07557251
- SN2001Phase 1 · NCT07059403
- Tune-401Phase 1 · NCT06671093
- TVAX-028Phase 1 · NCT07673068
- WGc0201Phase 1 · NCT07051187
- Hepatitis B Immunoglobulin (HBIg)Early phase 1 · NCT07328711
- Peginterferon alfa-2bEarly phase 1 · NCT07553767
- PEGylated recombinant human interferon alpha-2b injectionEarly phase 1 · NCT05922306
- TMFEarly phase 1 · NCT07553767
Closest to patients
- Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B InfectionStudy to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B InfectionSpitalul Clinic de Boli Infecțioase și Pneumoftiziologie "Victor Babeș" Craiova · Craiova, Romania + 19 more hospitalsPhase 3Primary completion 2017
- Entecavir to TAF SwitchEntecavir to TAF SwitchThomas Jefferson University · Philadelphia, United StatesPhase 3Primary completion 2020
- Antiviral Prophylaxis and Infant Vaccination to Prevent Perinatal Hepatitis B InfectionAntiviral Prophylaxis and Infant Vaccination to Prevent Perinatal Hepatitis B InfectionMahosot Hospital · Vientiane, Laos + 19 more hospitalsPhase 3Primary completion 2023
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Case report
[Sustained disease control with sacituzumab govitecan in a patient with HR+/HER2- metastatic breast cancer resistant to endocrine therapy, with a high tumour burden and limited benefit from standard chemotherapy.].
[Sustained disease control with sacituzumab govitecan in a patient with HR+/HER2- metastatic breast cancer resistant to endocrine therapy, with a high tumour burden and limited benefit from standard chemotherapy.].
Recenti progressi in medicina
PubMed · PMID 42979888Case report
Rare Case Report: Therapy-Related Acute Promyelocytic Leukemia (t-APL) in a Young Non-HBV Female After TACE Plus Sintilimab-Lenvatinib for HCC - A Clinical Alert and Literature Review.
Rare Case Report: Therapy-Related Acute Promyelocytic Leukemia (t-APL) in a Young Non-HBV Female After TACE Plus Sintilimab-Lenvatinib for HCC - A Clinical Alert and Literature Review.
Journal of hepatocellular carcinoma
PubMed · PMID 42979222Publication
Patient-reported treatment burden, communication, and persistence intention during add-on peginterferon alfa-2b therapy for chronic hepatitis B: a cross-sectional study.
Patient-reported treatment burden, communication, and persistence intention during add-on peginterferon alfa-2b therapy for chronic hepatitis B: a cross-sectional study.
Frontiers in public health
PubMed · PMID 42978650
Organisations that can help
Helplines, patient groups and support services for you and your family.
International & European
European Liver Patients' Association (ELPA)
European umbrella of national liver patient groups: liver disease information, HCC patient guide (with ESMO), clinical trial finder and liver cancer advocacy; points patients to member groups.
Visit site: European Liver Patients' Association (ELPA)European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
Visit site: European Patients' Forum (EPF)Hepatitis B Foundation
US-based nonprofit working worldwide for people with hepatitis B and D; patient information in 16+ languages, online support groups, physician directory, clinical trials info, international programmes. Not a federation.
Visit site: Hepatitis B FoundationInternational Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Visit site: International Alliance of Patients' OrganizationsWorld Hepatitis Alliance
Global network of organisations of people affected by viral hepatitis; World Hepatitis Day, advocacy for elimination by 2030, community research, free Community Impact Programme course.
Visit site: World Hepatitis Alliance
Frontlight is not affiliated with these organisations; we list them because they help.
Checked automatically every 90 days.
Find fellow researchers
Groups with active Hepatitis B work.
Fudan University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Southern Medical University
Guangzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
Peking University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Zhejiang University
Hangzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
Fujian Medical University
Fuzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
University of Hong Kong
Pok Fu Lam, Hong Kong SAR China
Team details appear once the team leader joins.
Is this your team? Claim it
Chinese PLA General Hospital
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
Shanghai Jiao Tong University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Nanfang Hospital
Guangzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it